Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Moss

Showing results (291-300 of 308) with videos related to

Pageof 31
Sort By:
Journal of Virology|October 8, 2020
Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV ProteomeMauricio A Martins, Lucas Gonzalez-Nieto, Michael J Ricciardi, et al.
Vaccine|January 12, 2012
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challengeJosephine H Cox, Maria G Ferrari, Patricia Earl, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Nature|March 12, 2004
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxPatricia L Earl, Jeffrey L Americo, Linda S Wyatt, et al.
The Journal of Infectious Diseases|October 11, 2003
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaquesYvette Edghill-Smith, David Venzon, Tatiana Karpova, et al.
Science Translational Medicine|March 27, 2024
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaquesCatherine Jacob-Dolan, Darren Ty, David Hope, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Vaccine|May 2, 2002
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineRama Rao Amara, Francois Villinger, John D Altman, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Plos One|April 16, 2015
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trialPatricia J Munseri, Arne Kroidl, Charlotta Nilsson, et al.
Pageof 31

Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
Journal of Virology|October 8, 2020
Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV ProteomeMauricio A Martins, Lucas Gonzalez-Nieto, Michael J Ricciardi, et al.
Vaccine|January 12, 2012
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challengeJosephine H Cox, Maria G Ferrari, Patricia Earl, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Nature|March 12, 2004
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxPatricia L Earl, Jeffrey L Americo, Linda S Wyatt, et al.
The Journal of Infectious Diseases|October 11, 2003
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaquesYvette Edghill-Smith, David Venzon, Tatiana Karpova, et al.
Science Translational Medicine|March 27, 2024
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaquesCatherine Jacob-Dolan, Darren Ty, David Hope, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Vaccine|May 2, 2002
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineRama Rao Amara, Francois Villinger, John D Altman, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Plos One|April 16, 2015
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trialPatricia J Munseri, Arne Kroidl, Charlotta Nilsson, et al.
Pageof 31